Cubist Pharmaceuticals

Cubist Pharmaceuticals, Inc.
Company type	Subsidiary
Traded as	Nasdaq: CBST
Industry	Pharmaceuticals (Biopharmaceuticals & Biotherapeutics)
Founded	1992; 32 years ago
Defunct	2015
Headquarters	Lexington, Massachusetts
Key people	Robert J. Perez (president & CEO)
Products	Product Pipeline
Revenue	$926.4 million USD (2012)
Parent	Merck & Co.
Website	www.cubist.com

Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.

.^[1] The company employed 638 people, mostly in Lexington, Massachusetts.^[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).^[3]

History

Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.^[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.^[5]

In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.^[6]

The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.

In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.^[7]

In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.^[8]

In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.

Products

The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.^[9] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium-fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).^[10]

In 2011, its product pipeline focused on gram-negative bacterial infections,^[11] Clostridioides difficile infection,^[12] and respiratory syncytial virus.^[13]

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.^[14]^[15]

References

^ Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.
^ "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.
^ Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014
^ "SEC Form S3 Cubist Pharmaceuticals, Inc". March 8, 2000.
^ "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.
^ "Cubist Profit Down 53%", Drug Discovery & Development, Advantage Business Media, 19 Jan 2012, retrieved 22 Jan 2012 – via Associated Press
^ Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
^ Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.
^ "Cubist Settles Teva Patent Litigation on Antibiotic Cubicin". Bloomberg. 2011-04-05. Retrieved 28 May 2011.
^ "Optimer to Market Dificid Drug With Cubist Pharmaceuticals". Bloomberg. 2011-04-06.
^ Donnelly, Julie M. (13 December 2011). "Cubist advances antibiotic for Gram-negative bacteria". www.bizjournals.com. Retrieved 2017-10-31.
^ Brown, Rodney H. (6 April 2011). "Cubist – Optimer diarrhea drug could net $47M". www.bizjournals.com. Retrieved 2017-10-31.
^ "Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs". GenomeWeb. Retrieved 2017-10-31.
^ Michael r. Page, Pharmd (17 September 2014). "Sivextro by Cubist Pharmaceuticals". www.pharmacytimes.com. September 2014. 3 (5). Retrieved 2017-10-31.
^ "Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review | FierceBiotech". www.fiercebiotech.com. 30 December 2013. Retrieved 2017-10-31.

42°25′25.2″N 71°14′32.9″W / 42.423667°N 71.242472°W / 42.423667; -71.242472

[1] Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.

[2] "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.

[3] Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014

[4] "SEC Form S3 Cubist Pharmaceuticals, Inc". March 8, 2000.

[5] "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.

[apcubist2012-6] "Cubist Profit Down 53%", Drug Discovery & Development, Advantage Business Media, 19 Jan 2012, retrieved 22 Jan 2012 – via Associated Press

[7] Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.

[8] Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.

[9] "Cubist Settles Teva Patent Litigation on Antibiotic Cubicin". Bloomberg. 2011-04-05. Retrieved 28 May 2011.

[10] "Optimer to Market Dificid Drug With Cubist Pharmaceuticals". Bloomberg. 2011-04-06.

[11] Donnelly, Julie M. (13 December 2011). "Cubist advances antibiotic for Gram-negative bacteria". www.bizjournals.com. Retrieved 2017-10-31.

[12] Brown, Rodney H. (6 April 2011). "Cubist – Optimer diarrhea drug could net $47M". www.bizjournals.com. Retrieved 2017-10-31.

[13] "Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs". GenomeWeb. Retrieved 2017-10-31.

[14] Michael r. Page, Pharmd (17 September 2014). "Sivextro by Cubist Pharmaceuticals". www.pharmacytimes.com. September 2014. 3 (5). Retrieved 2017-10-31.

[15] "Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review | FierceBiotech". www.fiercebiotech.com. 30 December 2013. Retrieved 2017-10-31.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

History

Products

References

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.